Stimulation of fat lipolysis(fat burning)
Neurotherapeutics 20 , 12291240 (United States, 2023)
CCE Launches "Peptide Practice Verification"
Audit trigger and potential underpayment
A separate high-dose extrapolation lands near 650 mg/day based on mouse-to-human allometric scaling, but no human has been studied at any dose
You may also like Product Description DSIP Peptide | Buy DSIP UK | Research Use Only DSIP Delta Sleep-Inducing Peptide is a naturally occurring amphiphilic nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, MW 849 Da) first isolated from rabbit cerebral venous blood in 1977 by the Schoenenberger-Monnier group at the University of Basel, found in both free and bound forms in the hypothalamus, limbic system, pituitary, gut, pancreas, and body fluids, that in pre-clinical and limited clinical research demonstrates a uniquely broad neuromodulatory profile promoting delta-wave slow-wave sleep (SWS), modulating corticotropin and GH release, exerting stress-protective and adaptogenic activity, reducing mitochondrial oxidative stress under hypoxia, demonstrating anticonvulsant and antinociceptive activity, accelerating motor research applications post-stroke, and exhibiting geroprotective and anticarcinogenic properties in long-term murine studies making it one of the most pharmacologically diverse endogenous regulatory neuropeptides in the sleep and stress research literature, despite its receptor remaining formally unidentified
